Article
Engineering, Biomedical
Shuojiong Pan, Tianyu Li, Yizheng Tan, Huaping Xu
Summary: In this study, selenium-containing nanoparticles were constructed to synergistically enhance Pem-based chemotherapy and NK cell-based immunotherapy. The selenium compounds could deliver Pem to tumor sites and improve the chemotherapy efficiency. Additionally, they can also activate NK cell's immune response. The in vitro and in vivo experiments revealed the potential mechanism, highlighting the promising prospect of this strategy in chemoimmunotherapy.
Article
Biotechnology & Applied Microbiology
Peter J. J. Chockley, Jorge Ibanez-Vega, Giedre Krenciute, Lindsay J. J. Talbot, Stephen Gottschalk
Summary: In this study, researchers aimed to enhance the function of CAR immune cells by tuning the CAR immune synapses using an intracellular scaffolding protein binding site. The results showed that the synapse-tuned CAR immune cells exhibited increased effector cell functionality both in vitro and in vivo, leading to enhanced killing of tumor cells.
NATURE BIOTECHNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Kwang-Soo Kim, Dong-Hwan Kim, Dong-Hyun Kim
Summary: NK cell cancer immunotherapy plays a unique role but faces challenges such as the immune-suppressive tumor microenvironment, low activity of NK cells, and limited contact frequency of NK cells with tumor cells. Innovative strategies are needed to advance NK cell cancer immunotherapy.
Review
Pharmacology & Pharmacy
Idoia Mikelez-Alonso, Susana Magadan, Africa Gonzalez-Fernandez, Francisco Borrego
Summary: NK cells are lymphocytes with potent antitumor and antiviral functions, exhibiting memory-like responses. Various NK cell-based immunotherapies have been developed, with nanotechnology considered as an attractive option to enhance NK cell effector functions.
ADVANCED DRUG DELIVERY REVIEWS
(2021)
Article
Oncology
Masahiro Ohira, Ryuichi Hotta, Yuka Tanaka, Toshiharu Matsuura, Akin Tekin, Gennaro Selvaggi, Rodrigo Vianna, Camillo Ricordi, Phillip Ruiz, Seigo Nishida, Andreas G. Tzakis, Hideki Ohdan
Summary: The study explored the use of deceased donor liver-derived NK cells to prevent HCC recurrence after LT, suggesting that this treatment could be beneficial in preventing HCC recurrence. All patients who received this immunotherapy completed a follow-up of at least 2 years without evidence of HCC recurrence.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Grace Lee, Sheela Karunanithi, Bruce Posner, Hanspeter Niederstrasser, Hong Cheng, Yuriy Federov, Shivaprasad Manjappa, Karam Musaitif, Huaiyu Wang, Zachary Jackson, David Wald
Summary: Our work led to the identification of a promising compound that potently increases NK cell-mediated killing of a variety of different cancer cells, but has no impact on the killing of normal cells. This compound demonstrates the utility of this screening assay.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Immunology
Jack G. Fisher, Amber D. P. Doyle, Lara V. Graham, Salim I. Khakoo, Matthew D. Blunt
Summary: Disruption of the NKG2A:HLA-E interaction to enhance NK cell activation against cancer is a novel strategy for immunotherapy.
Article
Oncology
Mingzhu Pan, Fei Wang, Lidi Nan, Siyu Yang, Jinyao Qi, Jiajun Xie, Shuai Shao, Hongyi Zou, Min Wang, Fumou Sun, Juan Zhang
Summary: Anti-angiogenic therapy has shown significant clinical benefits in gastric cancer and non-small cell lung cancer. However, the immunosuppressive tumor microenvironment limits its effectiveness. Scientists have developed a bi-specific fusion protein to improve anti-angiogenic therapy and found that it can promote activation of natural killer cells, change the polarization of tumor-associated macrophages, and enhance anti-tumor activity when combined with PD-1 blockade.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Engineering, Biomedical
Liwen Fu, Weiying Zhang, Xiaojun Zhou, Jingzhong Fu, Chuanglong He
Summary: This study developed a novel nanoparticle platform loaded with Rh2 drug for the effective treatment of osteosarcoma, capable of triggering immunogenic cell death, enhancing immune responses, and inhibiting tumor growth.
BIOACTIVE MATERIALS
(2022)
Review
Oncology
Yanlin Yu
Summary: Innate immune natural killer (NK) cells can directly kill metastatic cancer cells without activation. The cytotoxicity and immune regulation of NK cells are controlled by a balance of activating and inhibitory receptors on the cells, while metastatic tumor cells have strategies to evade immune cell attacks. This review focuses on the critical role of NK cells in metastasis and the recent development of effective NK cell-based immunotherapies.
Article
Immunology
Kai Zhang, Enwu Yuan
Summary: This study created a unique prognostic profile based on NK cell marker genes that can accurately predict the efficacy of immunotherapy for HCC patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Gilles Berger, Erik H. Knelson, Jorge L. Jimenez-Macias, Michal O. Nowicki, Saemi Han, Eleni Panagioti, Patrick H. Lizotte, Kwasi Adu-Berchie, Alexander Stafford, Nikolaos Dimitrakakis, Lanlan Zhou, E. Antonio Chiocca, David J. Mooney, David A. Barbie, Sean E. Lawler
Summary: This study investigates the potential of a STING agonist called ADU-S100 in treating glioblastoma, an aggressive brain tumor. The results show that ADU-S100 can modulate the tumor microenvironment and enhance immune response, leading to improved survival in mouse models. The study also suggests the possibility of combining STING agonists with other immunotherapies for better treatment outcomes.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Immunology
Nohelly Derosiers, William Aguilar, David A. DeGaramo, Avery D. Posey
Summary: Despite the success in treating hematological malignancies, the effectiveness of chimeric antigen receptor T cell therapy against solid tumors is still limited due to the engagement of immune checkpoint molecules and glycoimmune interactions in the tumor microenvironment. This review discusses strategies to overcome the inhibitory PD-L1/PD-1 axis and highlights the importance of glycan-binding proteins in modulating T cell immunosuppression.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Immunology
Nicky A. Beelen, Merel R. Aberle, Virginia Bruno, Steven W. M. Olde Damink, Gerard M. J. Bos, Sander S. Rensen, Lotte Wieten
Summary: This study evaluated the cytotoxic potential of adoptive NK cells against pancreatic cancer organoids and found that ADCC-inducing antibodies can enhance NK cell anti-tumor responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Eilis Russell, Melissa J. Conroy, Martin P. Barr
Summary: Lung cancer, with NSCLC as the majority, is the leading cause of cancer-related deaths worldwide. Early lung cancer often presents with no symptoms, leading to late-stage diagnosis. Despite current treatments, many patients experience tumor relapse or develop therapeutic resistance, highlighting the need for more effective therapies.